JCEM: Long-term outcomes and treatment of persistent and transient congenital high insulinemia

The treatment of congenital high insulinemia (CHI) has been improved.
recently, a research paper was published in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, which explores the treatment and long-term outcomes of patients with persistent and transient CHI (P-CHI and T-CHI) in Finland.
review study of population-based CHI patients conducted between 1972 and 2015 involved 106 P-CHI patients and 132 T-CHI patients (42 diagnosed before 2000 and 196 diagnosed after 2000), with a medium follow-up time of 12.5 and 6.2 years, respectively.
the study were recovery, diabetes, pancreatic exocrine dysfunction, and neurodevelopment.
incidence of CHI (n-238) was 1:11,300 live births (1972-2015).
between 2000 and 2015, the occurrence rate of P-CHI (n=69) was 1:13500 and the occurrence rate of T-CHI (n=127) was 1:7400.
in the P-CHI patient group that occurred after 2000, high insulin drugs were started and lowered faster than early blood sugar.
68 percent of the 74 P-CHI patients who received the drug stopped taking the drug.
13 (12%) P-CHI patients underwent partial pancreatic excision, of which 19 (18%) underwent near-full pancreatic excision.
0% and 84% of these patients had diabetes, respectively, while 23% and 58% had clinical pancreatic exocrine dysfunction.
in the P-CHI and T-CHI groups, mild neurological abnormalities (21% and 16%, respectively) and intellectual disabilities (9% and 5%, respectively) were more common.
, however, the incidence of diabetes and pancreatic exocrine dysfunction was higher in patients with post-P-CHI neurodevelopment than in patients with P-CHI before 2000.
results show that the treatment and long-term efficacy of P-CHI patients have improved significantly since 2000 compared with earlier periods.